| [1] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
| [2] |
SHEN Chang, AI Kelong, HU Changping.
Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
|
| [3] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
| [4] |
FU Hong, TIAN Lei.
Individualized precision therapy for patients with ischemic stroke and hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
|
| [5] |
CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong.
Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
|
| [6] |
ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang.
Application of chronopharmacology in the hypertension treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
|
| [7] |
CUI Sumei, CUI Zhaoqiang.
Application of β-blockers for hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
|
| [8] |
LI Yuanfang, CUI Zhaoqiang.
Treatment of hypertension complicated with hyperuricemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
|
| [9] |
XU Jianfei, LIN Li.
Research progress in pharmacological and non-pharmacological treatments of hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
|
| [10] |
KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng.
Angiotensin receptor neprilysin inhibitor in elderly with hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
|
| [11] |
LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo.
Progress of hypertension pharmacological treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
|
| [12] |
MENG Shi, WANG Zhongqun.
Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
|
| [13] |
WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui.
Research progress of melatonin on pulmonary hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
|
| [14] |
XING Kai, GONG Jinyu, LUO Jianquan.
Advances on pharmacogenomics of diuretics-related adverse reactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
|
| [15] |
YE Peng, TAN Xing, LENG Yueqi, WANG Yangkai, WANG Weizhong.
Current opinions and developments of non-pharmacological treatments of hypertension based on sympathetic nervous system
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1335-1343.
|
